Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

g of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with U.S. and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and other genetic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

-- the potential that results of clinical or preclinical studies indicate

that product candidates are unsafe or ineffective,

-- our dependence on third parties in the conduct of our clinical studies,

-- a change in strategy by our collaboration partners,

-- delays or failure to achieve final agreement with regulatory

authorities on the design of phase 3 program for Amigal and the

regulatory pathway for approval of Amigal,

-- delays or failure to achieve regulatory approvals for our products,

-- risks of relying on third party manufacturers for the supply of our

product candidates,

-- our or licensors' inability to obtain, maintain and successfully<
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ill. , Jan. 15, 2014  Bill Jacobs Automotive, a ... , is teaming up with the Heartland Blood Center and ... blood drive. The drive takes place Saturday, Jan. 18 at ... - 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... of Angel Soft website Madison, Wis. Imagine, says ... that you actually want to watch it again and again. ... Soft toilet paper by international tissue and paper manufacturer Georgia-Pacific. ... asks him what he is doing," Ramsey told a crowd ...
... exceeded expectations, reaching $3.6 billion in 2002, according to a new ... 2005. , ,In 2002, the state ranked 20 th ... in academic R&D spending. , ,"You'd be hard-pressed to find ... few years," said David Ward, president of NorthStar Economics ...
... has announced the release of Centricity Physician Office ... for physicians that extends the functionality of Centricity Physician ... , , Centricity Physician Office Mobile ... and schedules and to capture charges from any location. ...
Cached Biology Technology:Consumer "engagement" stressed at e-Business seminar 2Consumer "engagement" stressed at e-Business seminar 3New report says Wisconsin R&D spending exceeding expectations 2
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized ... considered it to be essentially an affliction of primary motor ... that control muscle movement. , But in a new study ... Neuron , a team of scientists at the University of ...
(Date:4/16/2014)... director of the Physical Biosciences Division of Lawrence Berkeley ... recognized as a leading authority on the evolutionary design ... to systems and synthetic biology, has been named one ... Award by U.S. Energy Secretary Ernest Moniz. The E.O. ...
Breaking Biology News(10 mins):For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3
... University of Wisconsin School of Medicine and Public Health ... taking part in a novel clinical trial investigating if ... of severe coronary artery disease. , The trial, just ... in the Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia (ACT34-CMI) ...
... but also too much iron is bad for our ... where it can lead to organ failure and even ... Researchers from the Innsbruck Medical University, the University of ... now made a surprising discovery that may lead to ...
... play a pivotal role in the inception of Darwin’s theory ... their significance when he collected them during his voyage on ... predict the impact the vast amount of marine microbial DNA ... J. Craig Venter, Ph.D., and his team ?will have on ...
Cached Biology News:UW launches study testing adult stem cells for heart damage repair 2UW launches study testing adult stem cells for heart damage repair 3Putting an old drug to a new use 2Darwin's famous finches and Venter's marine microbes 2Darwin's famous finches and Venter's marine microbes 3Darwin's famous finches and Venter's marine microbes 4Darwin's famous finches and Venter's marine microbes 5
... This complete kit contains enough ... from a total of 5 ... and includes the StemSep red ... reagents and buffers for the ...
... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
... Product Mouse monoclonal [1320] to RFC1 ... subunit of human Replication Factor C expressed in ... with Human and S. cerevisiae. Not yet tested ... subunit of RFC1 Background Information ...
... enzyme glycerol 3-phosphate dehydrogenase catalyzes a ... and glycerol 3-phosphate, with NAD as ... during differentiation of progenitor cells into ... this enzyme has been used as ...
Biology Products: